IFI-M · PAB Tri-Axis Dominant-Primary Series

Specimen SS-F-M3-01577 // MULTI-AXIS · IFI-M

PAB Tri-Axis Dominant-Primary Series I-BL

Brassica nigra

Black Mustard

Tier IPAB Tri-Axis Dominant-Primary Series

Target Trait

1.1×

fold-change

Sharp-dominant tri-axis A+B modulated fold-change

Technical Specifications

SKU

SS-F-M3-01577

Genomic Edits

6

GC Content

48.2%

Construct Length

4,080 bp

Promoter System

CaMV 35S / Ubiquitin

Expression System

Biolistic transformation

Host Strain

Particle Gun

Receptor Target

TRPA1 + Polyphenol-astringency axis + TAS2R38 (suppression)

IFI Score

110

Pathway Edits

  • TRPA1 pathway primary gene cluster for sharp (IFI-P) tri-axis component
  • Polyphenol-astringency axis pathway primary gene cluster for astringency (IFI-A) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent PAB pathway operation
  • Cross-pathway regulatory circuit for sharp-dominant PAB triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPA1, Polyphenol-astringency axis, and TAS2R38 (suppression) pathways simultaneously engineeredSharp-dominant tri-axis expression strategy (PAB) with cross-pathway flux managementBiolistic co-bombardment of multi-axis transgene cassettes for high-copy integration events

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier I PAB triple-axis construct for advanced multi-modal sensory architecture combining sharp, astringency, and bitter-attenuation axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$299 · Tier I License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?